Arcus Biosciences at Citi summit: casdatifan data loom large

On September 9, 2026, Arcus Biosciences presented its casdatifan, a HIF-2α inhibitor for clear cell renal cell carcinoma, at Citigroup's Biopharma Back to School Summit. The company highlighted promising early and mid-stage data on casdatifan, but also pointed to a key near-term risk: investors need to see if casdatifan can deliver an overall survival advantage over strong progression-free survival.

Arcus claimed casdatifan has a superior pharmacokinetic profile compared to Merck's belzutifan, with dose-proportional and linear behavior that may allow deeper target engagement. They plan to release new data in October on casdatifan's late-line monotherapy, PEAK-1 second-line study, and first-line combination programs. Late-line monotherapy data shows a progression-free survival of 12-15 months, compared to belzutifan's 5.6 months in LITESPARK-005.

Arcus estimates its first-line program could have a market opportunity of $4 billion or more, while the second-line program represents $1.5 billion to $2 billion. They emphasized that the October update will provide the first overall survival data for casdatifan in this setting, which could be a significant differentiator for commercialization in both the U.S. and internationally.